Drug companies like Pfizer are trying to develop female libido drug

Across the globe, some 40 percent of women actually suffer from low libido, or what is medically termed as female sexual arousal disorder (FSAD). Women suffering from this condition fail to achieve orgasm during sexual encounters.

Though there is currently no such drug available in the market, pharmaceutical magnate Pfizer, is taking a huge step in making this female drug a possibility in the future. Tests for the development of the drug have commenced on animals, particularly in rabbits.

This most recent study, which was developed by a group of British researchers led by Chris Wayman, established that by injecting the drug accompanied by arousing the bunnies, the drug paves way to an improved blood flow to the arousal region, thereby significantly improving the arousal in the subjects.

These findings are significant as the drug aims to trigger, not the initiation of desire in women, but the stimulation of arousal through increased blood flow to the genitals. Wayman stated that a woman becomes sexually aroused and well-lubricated when the brain sends signals to the body for an increased blood flow to the center of arousal to encourage relaxation of the vaginal muscle, also escalating the chances for an orgasm.

Currently, a feasible drug is yet to be fully developed. Nevertheless, Pfizer is providing a promising future for the possible existence of a “female Viagra”.